Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Cyst Fibros. 2015 Jul 10;15(4):518–530. doi: 10.1016/j.jcf.2015.06.005

Table 1.

Antimicrobial interference study in normal (non-neutropenic) and neutropenic mice treated with tobramycin (n = 5/survival group; 3/bacterial recovery group) with and without D-met. The addition of D-met to tobramycin treatment did not significantly influence survival (p = 0.444) or mean bacterial recovery (p = 0.197).

Swiss Webster mouse in vivo model
Normal Mice Neutropenic Mice
Treatment % Survival Mean Bacterial Recovery % Survival Mean Bacterial Recovery
Saline Only 100 0 100 0.5 × 101
Isolate Only 0 8.33 × 104 80 1.35 × 105
Tobramycin1 + Isolate 60 0.33 × 101 40 1.17 × 101
D-met2 + Isolate 0 5.17 × 104 0 8.47 × 104
Tobramycin + D-met3+ Isolate 100 1.75 × 102 100 4.8 × 101
1

Tobramycin dosage: tobramycin (15 mg/kg)

2

D-met dosage: (200 mg/kg)

3

Dosage combinations: tobramycin (15 mg/kg) + D-met (200 mg/kg)